The U.S. Food and Drug Administration on October 1, 2026, approved the Autus Size-Adjustable Valve, the first heart valve designed to grow with children. Made by Edwards Lifesciences, the expandable heart valve is meant for young patients with congenital pulmonary valve disease and could reduce how many open-heart surgeries they need as they grow.
- What: FDA premarket approval for the Autus Size-Adjustable Valve, a surgical pulmonary valve for children.
- Who makes it: Edwards Lifesciences. The valve was developed by Autus Valve Technologies.
- How it grows: It is implanted at about 13 mm and can be widened up to 22 mm, an adult size, using a balloon catheter.
- First of its kind: It is the first heart valve approved in the U.S. with leaflets made of a polymer rather than animal tissue.
- Evidence: A study of 62 children at 12 U.S. sites, with follow-up planned for 10 years.
[IMAGE 1: Medical illustration or diagram of the human heart showing the pulmonary valve]
Why children need a heart valve that grows
The pulmonary valve controls blood flow from the heart’s right side to the lungs. Some babies are born with a pulmonary valve that is too narrow (stenosis) or that never formed properly (atresia). Others develop a leaking valve (regurgitation) after earlier repairs. According to the FDA, about 4,200 babies a year in the U.S. are affected by pulmonary atresia or stenosis.
Many of these children eventually need a replacement valve. The problem is that a fixed-size valve does not grow. As a child gets bigger, the valve becomes too small and must be replaced, which has often meant several open-heart operations during childhood. Each operation brings its own recovery time and risks.
How the expandable heart valve works
Surgeons implant the Autus valve at a small size suited to a toddler or preschool child, about 13 mm in diameter. As the child grows, doctors can widen it in a minimally invasive procedure. A thin tube with a small balloon (a balloon catheter) is guided through a blood vessel to the valve and inflated to stretch it to a larger size.
The valve can be expanded step by step up to about 22 mm, which the FDA describes as adult-sized. The aim is to replace repeat open-heart surgery with these less invasive catheter procedures. Dr. Michelle Tarver, who leads the FDA’s device center, said the valve gives doctors the option of “far fewer trips to the operating room.”
The valve’s leaflets, the flaps that open and close with each heartbeat, are made from a polymer. Every heart valve previously approved in the U.S. used leaflets made from animal-derived tissue, according to the FDA and trade publication MassDevice.
[IMAGE 2: Pediatric cardiac surgery team or catheterization lab (generic, no identifiable patients)]
What the clinical study showed
The approval was based on a study of 62 pediatric patients at 12 sites in the U.S. The FDA and Edwards reported the following results.
| Measure | Reported result |
|---|---|
| Procedure success | All implant procedures successful (FDA) |
| Deaths, blood clots or strokes | None reported (FDA) |
| 6-month valve performance | 60 patients had acceptable function with no more than mild leakage (FDA) |
| Device-related complications at 30 days | None (Edwards) |
| Valve re-interventions through 6 months | None (Edwards) |
| Valves expanded during the study | 2 patients, both successfully (FDA) |
The study also recorded problems. The FDA said three patients had fractures in the valve frame and two had reduced leaflet movement, which caused no symptoms. Only two valves had been expanded at the time of the review, so evidence on repeated expansions over many years is still limited. Edwards said patients will be followed for 10 years.
Why the FDA approval matters
The device went through premarket approval, the FDA’s strictest review route for high-risk Class III devices. It had earlier received Breakthrough Device designation, which is meant to speed development of promising technology. It is also the first children’s device approved through the FDA’s Total Product Life Cycle Advisory Program, known as TAP.
Acting FDA Commissioner Kyle Diamantas called the decision “a historic turning point.” Edwards did not give a launch date or price in its announcement.
What happens next
Doctors and hospitals will now decide which children are suitable for the valve. The 10-year follow-up will show how well the valve holds up as children grow and how often it needs to be expanded. Families of children with pulmonary valve disease should talk with their child’s cardiology team about whether it is an option.
This article is for general information only. Please consult a qualified medical professional about any health condition or treatment.
FAQ
What is the Autus Size-Adjustable Valve?
It is a surgical pulmonary heart valve for children, made by Edwards Lifesciences. It can be widened after surgery as the child grows. The FDA approved it on October 1, 2026.
Who is the valve for?
It is for children with congenital pulmonary valve disease, such as pulmonary stenosis, pulmonary atresia or pulmonary regurgitation, who need the valve replaced.
Does it remove the need for all future surgery?
Not necessarily. It is designed to reduce repeat open-heart surgeries, but expansions still require catheter procedures, and long-term data are still being collected.
